These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33862461)

  • 1. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E
    Yoshino K; Hosooka T; Shinohara M; Aoki C; Hosokawa Y; Imamori M; Ogawa W
    Biochem Biophys Res Commun; 2021 Jun; 557():62-68. PubMed ID: 33862461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
    Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
    Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice.
    Tanaka K; Takahashi H; Katagiri S; Sasaki K; Ohsugi Y; Watanabe K; Rasadul IMD; Mine K; Nagafuchi S; Iwata T; Eguchi Y; Anzai K
    Am J Physiol Endocrinol Metab; 2020 Apr; 318(4):E492-E503. PubMed ID: 32017594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice.
    Naznin F; Sakoda H; Okada T; Tsubouchi H; Waise TM; Arakawa K; Nakazato M
    Eur J Pharmacol; 2017 Jan; 794():37-44. PubMed ID: 27876617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation.
    Kabil SL; Mahmoud NM
    Eur J Pharmacol; 2018 Jun; 828():135-145. PubMed ID: 29608898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.
    Xu Z; Hu W; Wang B; Xu T; Wang J; Wei D
    Yonsei Med J; 2022 Jul; 63(7):619-631. PubMed ID: 35748073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Green Tea Lowers Hepatic COX-2 and Prostaglandin E2 in Rats with Dietary Fat-Induced Nonalcoholic Steatohepatitis.
    Chung MY; Mah E; Masterjohn C; Noh SK; Park HJ; Clark RM; Park YK; Lee JY; Bruno RS
    J Med Food; 2015 Jun; 18(6):648-55. PubMed ID: 25453513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
    Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
    FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
    Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
    Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
    Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
    Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
    Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation.
    Yang X; Liu Q; Li Y; Ding Y; Zhao Y; Tang Q; Wu T; Chen L; Pu S; Cheng S; Zhang J; Zhang Z; Huang Y; Li R; Zhao Y; Zou M; Shi X; Jiang W; Wang R; He J
    Br J Pharmacol; 2021 Apr; 178(8):1756-1771. PubMed ID: 33480065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
    Liang Y; Arakawa K; Ueta K; Matsushita Y; Kuriyama C; Martin T; Du F; Liu Y; Xu J; Conway B; Conway J; Polidori D; Ways K; Demarest K
    PLoS One; 2012; 7(2):e30555. PubMed ID: 22355316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
    Tahara A; Takasu T
    Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.